News

Clarient has previously launched its first predictive biomarker for colorectal cancer which detects mutations in the KRAS gene. Ron Andrews, CEO of Clarient, said: “In conjunction with KRAS,

Dr Vetticaden will be a member of Cubist’s executive team and report to Mike Bonney, Cubist’s president and CEO. Dr Vetticaden will lead the development and implementation of

Prospective data from the clinical study is expected to be used to support a submission to the FDA and other regulatory jurisdictions for market clearance of the 3M

The company’s Phase III clinical trial of prGCD is designed as a multi-center, randomized, double-blind, parallel group, dose-ranging trial to assess the safety and efficacy of prGCD in

According to the company, NGX267 met the primary endpoint of a statistically significant increase in salivary flow production compared to placebo at all three doses: 10mg, 15mg, and

According to the company, the Mako Tactile Guidance System (TGS) is a surgeon-interactive tactile platform that incorporates a robotic arm and patient-specific visualization technology and prepares the knee

Most recently, Dr Shannon has served as head of global development at Novartis Pharma in Basel, Switzerland. Dr Shannon has received his undergraduate and postgraduate degrees from Queen’s

Under the agreement, Mylan is provided a patent license that will enable the company to market letrozole tablets, 2.5mg, prior to the expiration of US patent. Additional terms

Mr Elliot joins Tyrx from Valam, a provider of laser-based antimicrobial and vascular plaque destruction therapies, where he was president and CEO and remains a board director. Prior